Twelve Barrett's adenocarcinomas have been analysed for the occurrence of allelic imbalance (LOH) on chromosome 17 using 41 microsatellite markers. This study provides evidence for 13 minimal regions of LOH, six on 17p and seven on 17q. Four of these centre in the vicinity of the known tumour suppressor genes (TSGs) TP 53 (17p13.1), NF1 (17q11.2), BRCA1 (17q21.1), and a putative TSG (17p13.3). The tumours all displayed relatively small regions of LOH (1 ± 10 cM), and in several tumours extensive regions of LOH were detected. One tumour displayed only two very small regions of LOH; 17p11.2 and 17p13.1. The frequency of allelic imbalance has been calculated based on the LOH encompassing only one minimal region, and based on all the LOH observations. By both evaluations the highest LOH frequencies were found for regions II (p53), III (17p13.1 centromeric to p53), IV (17p12), V (17p11.2) and VII (NF1, 17q11.2). Our data supports the existence of multiple TSGs on chromosome 17 and challenges the view that p53 is the sole target of LOH on 17p in Barrett's adenocarcinoma.
Introduction
The incidence of Barrett's oesophageal adenocarcinoma (BOA) has risen faster than any other gastrointestinal tumour over the last 30 years, yet its prognosis remains poor (Cameron, 1993 ). Barrett's cancer is preceded in most cases by the metaplastic abnormality Barrett's oesophagus in which the normal squamous epithelium of the oesophagus is replaced by metaplastic columnar epithelium (Cameron et al., 1995) . This confers an increased risk for the development of adenocarcinoma of up to 100-fold. Barrett's oesophagus in turn arises in approximately 10% of patients with chronic gastroesophageal re¯ux disease (Fennerty et al., 1993; Stein and Stewart, 1993) . A sequence of histological changes marks the progression to adenocarcinoma (Cameron and Lomboy, 1992) . Histophathological surveillance however is insucient to eciently predict the disease outcome and the feasibility of using molecular markers as indicators of malignancy potential is currently attracting attention (Wright and Kingsnorth, 1994; Nakamura et al., 1994; Krishnadath et al., 1995; Saunter et al., 1995) .
An accumulation of genetic abnormalities aecting multiple tumour suppressor genes (TSGs) and oncogenes is the molecular basis of cancer development (Weinberg, 1991; Knudson, 1993) . Genetic alterations involving the p53 TSG are amongst the most commonly found abnormality, present in many dierent tumours (Harris and Hollstein, 1993; Greenwald et al., 1992; Wang and Wang, 1996) . In Barrett's oesophagus loss of heterozygosity (LOH), mutation and overexpression of the p53 TSG occurs frequently and in most cases precedes the development of invasive cancer (Gleeson et al., 1995; Krishnadath et al., 1995; Flejou et al., 1994; Casson et al., 1994; Blount et al., 1994; Galipeau et al., 1996; Audrezet et al., 1996; Campomenosi et al., 1996; Neshat et al., 1994; Gonzalez et al., 1997) . Other genetic abnormalities found in BOA include LOH, homozygous deletion and mutation within the MTS1/p16 TSG at 9p21 (Gonzalez et al., 1997; Barrett et al., 1996a) , LOH on 5q, 13q and 18q Blount et al., 1993) , aneuploidy (Barrett et al., 1996b; Blount et al., 1994; Galipeau et al., 1996) , and the ampli®cation and overexpression of certain oncogenes, notably c-erbB-2 and EGF-R. (Filipe and Jankowski, 1993; AlKasspooles et al., 1993; Nakamura et al., 1994) .
There are three known TSGs on chromosome 17 all of which are frequently altered in a number of tumours (Futreal et al., 1992; Seizinger, 1993; Knudson, 1973; Harris and Hollstein, 1993; Gullick, 1990) . These comprise p53 at 17p13.1; the hereditary neurofibromatosis gene NF1 at 17q11.2; and BRCA1, the familial breast/ovarian cancer gene at 17q21.1. We have also localized the hereditary tylosis oesophageal cancer gene TOC to within a 1 cm region at 17q25 (Risk et al., 1994; Kelsell et al., 1996) . From LOH studies in a variety of tumours there is also substantial evidence for the existence of a TSG telomeric to p53 at 17p13.3 (White et al., 1996; Kirchweger et al., 1994; Phillips et al., 1993; Nagai et al., 1995) , and candidate genes involved in ovarian cancer have been reported in this region (Wales et al., 1995; Schultz et al., 1996) . A region at 17q21 close to but distinct from BRCA1 has also been described that contains the candidate genes nm23.H1, plakoglobin and prohibitin (Sato et al., 1992; Alessandra et al., 1995; Aberle et al., 1995) . Moreover, numerous other distinct regions of allelic imbalance have been reported on chromosome 17 suggesting the presence of multiple other TSGs on this chromosome (Cornelus et al., 1993; Phillips et al., 1993; Cropp et al., 1993; Nagai et al., 1995; Kirchweger et al., 1994; Kerangueven et al., 1997; Fong et al., 1995; Neideracher et al., 1997; Phelan et al., 1998) .
In addition, monosomy or LOH involving the entire 17p or 17q arms is a common occurrence (reported mainly in ovarian cancer) (Neideracher et al., 1997; Pieretti et al., 1995) , and this has greatly hindered attempts to de®ne small common minimal regions of allelic imbalance. A further problem particularly in some tumour types is a variability in the degree of LOH detected for dierent markers which most likely represents clonal heterogeneity. This can cause ambiguity in the de®nition of the intervening heterozygous sites between regions displaying LOH. Further confusion regarding the common target sites of LOH on chromosome 17 has arisen from the use of dierent markers in dierent studies, many of which have not been precisely mapped.
In this study we have attempted to de®ne the target sites of LOH on chromosome 17 in 12 BOA specimens by introducing a number of re®nements to our approach. We have used over 40 precisely ordered markers on chromosome 17 for LOH analysis selected from the Genome Database, the majority of which have been mapped to YAC contigs. We have also given each case with LOH a score re¯ecting the degree of allelic imbalance observed which has allowed us to distinguish between regions of clear versus marginal LOH. In addition, we have used microscopically microdissected tumour DNA from fresh frozen oesophagectomy and biopsy specimens to achieve maximum tumour purity and PCR quality. Using these approaches we have demonstrated the presence of 13 clearly de®ned minimal regions of allelic imbalance on chromosome 17 in BOA tumours, six on 17p and seven on 17q (seven of which represent novel sites not presently associated with any known or candidate TSGs).
Results
The analysis of allelic imbalance (LOH) was carried out on normal and tumour DNA derived from microscopically micro-dissected tissue taken from six oesophagectomy specimens (A ± F), and six BOA biopsy specimens (G ± M) (see Materials and methods). Oesophageal squamous epithelium or gastric columnar epithelium at the upper and lower resection lines respectively was sampled to provide normal DNA.
A total of 41 markers were used to analyse 12 tumours (23 on 17p and 18 on 17q). All the informative loci were scored 0 or 1,3,5,7 or 9, 0 representing no detectable LOH, 1 representing the smallest marginal detectable LOH (*10%), and nine representing almost complete LOH (590%).
All the heterozygous sites involving only one analysed marker that lay between two regions of LOH were tested at least three times to ensure the accuracy of the heterozygous assignment. Similarly, all the sites of marginal LOH (scores 1, 3 and 5) were tested repeatedly and an average score was taken. The results were scored by eye by two independent researchers (JD and JG), and the UV Band gel scanning programme was used to check the accuracy of the scores. The majority of the repeated assays gave similar scores. Figure 1 shows the LOH map which we have generated based on the clear LOH observations (scores 5,7 and 9), and indicates the physical and cytogenetic location of the markers that were used. All of the tumours displayed allelic imbalance on chromosome 17 and carried interstitial regions of LOH of varying size. Several tumours exhibited small regions of LOH (*1-3 cm) e.g. LOH at TCF2 (specimen D), D17S804 (specimen E), and D17S1817 (specimen A). The majority also displayed LOH involving multiple consecutive markers frequently spanning a major portion of the chromosome. For example LOH on 17p in specimen A extended from D17S786 to D17S959 spanning approximately 33 cm; LOH on 17p in specimen H extended from the telomere to D17S959 spanning approximately 48 cm; and LOH on 17q in specimen B appears to have involved the whole arm (*75 cm). In several instances the boundary between two regions of LOH was de®ned only by one heterozygous marker (specimens B at D17S261, C at D17S954, E at D17S952 and D17S1603, G at D17S937, H at D17S925, I at D17S786 and J at D17S1857).
Overall the data indicates 13 common minimal regions (MRs) of LOH, six on 17p and seven on 17q. These regions are numbered I ± XIII in the direction 17pter-17qter (MR I ± XIII). Many uninterrupted regions of LOH spanned more than one MR and were not therefore used in their de®nition. It is the smaller sites of LOH that de®ne the MRs. Some of these small sites of LOH and the¯anking heterozygous sites are illustrated in Figure 2 . MRs II, VII and VIII encompass respectively the three known TSGs on chromosome 17 (p53, NF1 and BRCA1); four MRs encompass candidate TSGs, (MRs I, X, XI and VIII); and the remainder (MRs III, IV, V, VI, IX, XII and XIII) represent novel regions not associated with any known or candidate TSGs. MR V at 17p11.2 is de®ned by the greatest number of specimens (eight of the 12 examined), while the remaining MRs are de®ned by four (MRs I, III and VII), three (MRs IV, VI, X and XIII), two (MRs II, XI and XII) or one specimen (MRs VIII and IX). The most narrowly de®ned MRs comprise MR III, V and VI on 17p which are each in the order of 1 cm in size. Of the remainder, MRs II, IV and XI span 2-3 cm, MRs IV, VII, X and XII span 5 ± 8 cm and MRs I, VIII and XIII span over 13 cm.
Many regions of LOH spanned more than one MR and any one or more of the putative TSGs residing within these regions may have been the target of LOH. To assess the relative importance of each MR we have calculated the LOH frequency at each region based (a) only on the LOH observations involving a single MR (the minimum targeted LOH frequency) (MINT-LOH) and (b) based on all the LOH observations irrespective of the extent of the region involved (the maximum targeted LOH frequency) (MAXT-LOH). By both evaluations the highest LOH frequencies were found for MRs II, III, IV and V (17p), and MR VII (17q) (respective h Figure 1 The patterns of allelic loss on chromosome 17 in 12 Barrett's adenocarcinoma tumours and the minimal regions of loss identi®ed. =LOH (score 5 or more); homozygous; &=heterozygous (score 0 ± 4); m=microsatellite instability. Regions of uninterrupted loss are outlined in black; Isolated heterozygous sites involving a single marker within regions of loss. The position of markers on the cm map is shown (drawn to scale) and the corresponding approximate position on the cytogenetic map is indicated. The minimal regions are shown on the right aligned against the markers that are involved, and on the cm scale to indicate their physical location and size Multiple target sites on chromosome 17 in BOA J Dunn et al 60, 60, 78 and 63; 91, 82, 90 and 70) . This is followed by MRs I (17p), X, XII and XIII (17q) (respective MINT-LOH 50, 50, 43 and 38; MAXT-LOH 60, 58, 56 and 50), and MRs VI (17p), VIII, IX and XI (17q) (respective 10, 17 and 33; maxt % LOH 33, 25, 38 and 40) .
Discussion
The aim of this study has been to generate a detailed map of allelic imbalance (LOH) on chromosome 17 in BOA tumours and to identify the target regions that putatively contain TSGs involved in the development of this disease. A high incidence of LOH on the p arm of chromosome 17 and mutation of the P53 TSG at 17p13.1 are already well established features associated with the development of BOA, and there have been several studies reporting LOH frequencies at the P53 locus ranging from as high as 90 ± 100% (Gonzalez et al., 1997; Blount et al., 1994; Barrett et al., 1996b) . Furthermore, in many tumours chromosome 17 is one of the most important targets of LOH and numerous studies testify to highly complex patterns of allelic imbalance aecting many dierent regions of this chromosome (Cornelis et al., 1993; Phillips et al., 1993; Cropp et al., 1993; Nagai et al., 1995; Kirchweger et al., 1994; Kerangueven et al., 1997; Fong et al., 1995; Neideracher et al., 1997 ., Phelan et al., 1998 . We have conducted our study in anticipation of a similar complexity of LOH on chromosome 17 in Barrett's tumours, and a complication in discerning whether or not additional targets to p53 exist on 17p.
To achieve suciently high resolution LOH mapping to de®ne multiple target sites we have used 41 dierent markers that are precisely ordered along chromosome 17, being mostly anchored to YAC contigs. Our selected markers are particularly concentrated on 17p proximal to p53 which is a neglected region in other studies, yet one where we have previously noted very high LOH rates (Swift et al., 1995) . We have also used several clustered markers around 17q24 ± 25 where we have mapped the familial Tylosis oesophageal cancer gene (D17S1864 ± D17S785; Kelsell et al., 1996; Risk et al., 1994) . Combined with this detail, to maximize our DNA yields and PCR quality and to sample within regions of genetic uniformity, we have routinely performed careful micro-dissection on minute tissue samples from fresh frozen material. In addition, we have scored all our observations of allelic imbalance to dierentiate between marginal and clear sites of LOH and so provide an objective means of assessment of the integrity of each region of imbalance and each boundary to these regions.
All our analysed tumours displayed LOH on chromosome 17, particularly concentrated on 17p, and carried interstitial regions of allelic imbalance at many dierent locations varying in size from approximately 1 cm to over 50 cm. Overall, using a score of 5 or more for LOH (550% loss) we have identi®ed thirteen common minimal regions of LOH (MR I ± XIII), six of these on 17p and seven on 17q (Figure 1) . MR I spans *16 cm at 17p13.3, was de®ned in four specimens and displayed 60% LOH. There in now very good evidence from LOH studies in a variety of tumours for the existence of a TSG distal to p53. This includes breast, ovarian, cervical, brain and lung tumours (Neideracher et al., 1997; Keranguevan et al., 1997; Kirchweger et al., 1994; Nagai et al., 1995; Schultz et al., 1996; Phelan et al., 1998; Cornelis et al., 1994; Atkin and Baker 1989; Cogan et al., 1992; Saxena et al., 1992) . In ovarian tumours the site of this TSG has been localized to between D17S28 and D17S5 and the candidate genes OVCA1 and OVCA2 have been isolated from this region and been found to be under-expressed in most ovarian carcinomas (Shultz et al., 1996) . Another candidate gene HIC1 encoding a novel zinc ®nger protein is hypermethylated in a variety of cancers and its expression is methylationdependant (Wales et al., 1995) . More close range mapping of MRI will be required in BOA to determine whether exactly the same region of LOH detected in other tumours is involved in this cancer.
MR II spans *3 cm at 17p13.1 and was de®ned in two specimens. Our identi®cation of this region at the p53 locus is consistent with the established importance of p53 in BOA. In other studies on Barrett's tumours the concurrent ®nding of a high frequency of LOH at the p53 locus and a high frequency of p53 mutation has led to the implicit assumption that p53 is the sole target of loss on 17p (Gleeson et al., 1995; Galipeau et al., 1996; Blount et al., 1994) . We have also found a very high frequency of LOH at the p53 locus (82%). However, for seven of the nine tumours that displayed LOH at MR II the region involved extended well beyond p53 to encompass one of more of the other MRs we have identi®ed on 17p (Figure 1 ). For each case of p53 LOH there are therefore three possibilities, that the p53 gene is the sole target, a shared target, or not a target at all, and we suggest that despite a correlation, LOH at p53 should not be regarded as a marker of p53 inactivation. The MRs proximal to p53 (17p11.2 ± 13.) include MR III, IV, V and VI which span respectively 1, 6, 1 and 1 cm. These MRs displayed respectively 91, 82, 90 and 33% LOH and were de®ned in four, three, eight and three specimens. There have been few studies of LOH proximal to p53 on chromosome 17, despite isolated observations of a high frequency of loss in this region (Cornelis et al., 1993; Phillips et al., 1993; Kirchweger et al., 1994; Phelan et al., 1998) . In ovarian tumours one study does point to a minimal region at 17p12 ± 11.2 which encompasses the site of the MRs IV and V in our study (Phillips et al., 1993) . Recently metastatic suppressor activity has also been localized to within a 30 cm region proximal to p53 in prostate cancer (Chekmareva et al., 1997) . Our ®ndings strongly suggest that the proximal p arm of chromosome 17 contains a number of genes of relevance in BOA.
MR VII spans 8 cm, displayed 70% LOH and was de®ned in four specimens. This region encompasses the hereditary neuro®bromatosis gene NF1 which is an established recessive TSG involved in a variety of NF1-related and unrelated tumours (Seizinger, 1993) . Minimal regions of loss encompassing this gene have recently been reported in breast and ovarian tumours (Keranguevan et al., 1997; Wertheim et al., 1996) . Our data supports the signi®cance of this region of LOH in BOA, though further close range mapping would be required to assess the speci®c involvement of NF1.
MR VIII at 17q24 spans *8 cm, displayed 25% LOH and was de®ned by one specimen. This region encompasses the hereditary breast cancer gene BRCA1 as well as several other candidate TSGs (e.g. NM23, prohibitin and plakoglobin) (Sato et al., 1992; Alessandra et al., 1995; Aberle et al., 1995) , and has been shown to be an important region of LOH in a number of tumours especially breast and ovarian carcinomas (Cornelis et al., 1993; Kirchweger et al., 1994; Neideracher et al., 1997; Saito et al., 1993; Nagai et al., 1995; Sato et al., 1992; Mori et al., 1994; Gao et al., 1995) . Based on our study however, the signi®cance of this region in BOA remains doubtful.
MR IX (*3 cm) and MR X (*7 cm) displayed 38% and 58% LOH and were de®ned by one and three specimens respectively. High rates of LOH overlapping these regions at 17q24 ± 25 have been reported in other tumours principally breast and ovarian (Phelan et al., 1998; Cropp et al., 1993; Kirchweger et al., 1994; Fong et al., 1995) . The minimal regions between GH (growth hormone gene) and D17S21, and between D17S20 and D17S77 described in breast tumours appear to coincide most closely with MR IX and X (Cropp et al., 1993) . Interestingly growth suppressor activity in a breast cancer cell line has been localized to 17q24 ± 25 based on transfection studies with chromosome 17 hybrids containing de®ned deletions (Plummer et al., 1997) . Our results suggest that MR X is of signi®cance in BOA.
MR XI at 17q25 (*2 cm) displayed 40% LOH and was de®ned by two specimens. This region coincides with the site where we have mapped the hereditary tylosis gene (TOC), which in aected individuals confers a high risk for the development of oesophageal squamous cell carcinoma (SSC) (Risk et al., 1994; Risk et al., in preparation; Kelsell et al., 1996) . Large regions of loss surrounding this site have also been reported in other tumours (Phelan et al., 1998; Keranguevan et al., 1997; Kirchweger et al., 1994; Saito et al., 1993; Sato et al., 1992) . Moreover, we have recently reported the TOC locus to be a target of LOH in oesophageal SSC (von Brevern et al., 1998) . A full assessment of the signi®cance of MR XI in BOA however would require the analysis of further specimens.
MR XII (*5 cm) and XIII (*14 cm) at 17q25-qter displayed 56% and 50% LOH and were de®ned by two and three specimens respectively. These region also occur in the general vicinity where high levels of LOH have been found, and a minimal region coinciding with MR XIII has been reported in breast tumours (Phelan et al., 1998) , though there have been few other attempts to de®ne small target sites in this region. Our study suggests this region in signi®cant in BOA and warrants further analysis.
Despite our analysis of minute pure tumour samples we did detect considerable intra-sample variation in the degree of loss found at dierent loci. If this represents intra-tumour heterogeneity, those MRs that are de®ned by very clear LOH observations may be deemed of considerable signi®cance. A close examination of the LOH results in Figure 1 reveals that MRs I, III, IV, V and VI on 17p, and MRs XI and XII on 17q are de®ned by the clearest LOH observations (score 9=*90% LOH).
Many uninterrupted regions of LOH detected in this study spanned more than one MR and any one or more of these may have been the target. In addition to the overall LOH frequency at each MR (the maximum targeted LOH frequency) (MAXT-LOH), we have therefore also calculated the minimum targeted LOH frequency (MINT-LOH), based on LOH that involved only a single MR. We found a correlation between these two values, and the highest LOH frequencies for MR II (p53), III, IV and V on 17p and MR VII on 17q (MINT-LOH 50 ± 78%; MAXT-LOH 70 ± 91%), followed by MR I (17p), X, XII and XIII (17q) (MINT-LOH 38 ± 50%; MAXT-LOH 50 ± 60%). It may be of some signi®cance that the MRs III, IV and V centromeric to p53 on 17p display the highest LOH frequencies and are de®ned by an LOH score of 9.
We suggest that to unravel the complex patterns of LOH on chromosome 17 in BOA and other tumours, our approaches to LOH mapping hold several distinct advantages over those used in previous studies. The use of multiple precisely mapped markers provides detailed positional information, careful microscopic microdissection reduces intra/inter tumour heterogeneity in the analysed samples and the scoring of LOH allows existing heterogeneity to be re¯ected in the data. By continuing with the application of these approaches to the analysis of pre-malignant as well as tumour tissue we anticipate still further re®nement in the localization of the important targets sites of LOH on chromosome 17 and the provision of a starting point for the positional cloning of multiple novel TSGs.
Material and methods

Tissue specimens
Six biopsy and six oesophagectomy specimens were collected from the Royal Liverpool University Hospital, Department of Surgery, and from the Cardiothoracic Centre, Liverpool, UK. The tissue was cut into small blocks and snap frozen in isopentane (*30 s) then liquid nitrogen prior to storage at 7808C. Numerous tissue blocks were obtained from the oesophagectomy specimens so that those containing pure tumour or pre-malignant tissue could be selected for DNA extraction. The biopsy specimens were derived either from patients that had undergone an oesophagectomy or from suspect cancer patients during routine surveillance.
Micro-dissection and DNA extraction
Sections from each tissue block were H&E stained and histologically diagnosed (JRG). The blocks containing the largest regions of pure tumour were chosen for microdissection. From each block four 10 micron sections were cut immediately beneath the diagnosed section. These were stained for 10 s in 0.01% toluene blue and kept in water prior to micro-dissection. The sections were microdissected under the microscope using an ultra ®ne drawn out capillary. Normal tissue was similarly obtained from the micro-dissection of gastric columnar epithelium or oesophageal squamous epithelium derived from blocks at the resection margin that did not contain any identi®able tumour tissue. DNA was extracted from the tissue samples using the Nucleon II extraction kit (Scotlab) following the manufacturers instructions.
LOH analysis
Forty one microsatellite primers were selected covering the entire chromosome 17 whose order and precise location was known. This information was obtained from a number of genome project resources available on the WWW. Most of the chosen microsatellites have been mapped to YAC contigs. DNA from the biopsy and oesophagectomy tissue was serially diluted and titrated by PCR with a standard primer pair (D17S1864). The DNA concentration giving a faint but clear signal was used in all subsequent PCR reactions with the exception of a few adjustments made for certain primers. PCR reactions were performed in a 25 ml volume in standard buer (NH 4 buer, Bioline) containing 1.5 mM MgCl 2 200 mM dNTP, 5 pmol of each primer, and 0.5 units of Taq polymerase. The PCR parameters used for the MS markers were; 948C 5 M, then 25 cycles, 948C 30 s, 558C 30 s, 728C 30 s, and ®nally 728C 2 M. The MS PCR products were electrophoresed on a 10% polyacrylamide gel and viewed by silver staining. Allelic imbalance was assessed by eye, and by the use of the UV Band gel scanning programme (UVtech company), as described in the Results section.
